size-exclusion chromatography comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control for whey protein hydrolysate combines compositional and molecular tests. Protein content is measured by Kjeldahl or Dumas nitrogen determination. Moisture, ash, fat, and lactose are checked with standard food methods. The degree of hydrolysis is estimated by TNBS, OPA, or pH-stat procedures that quantify free amino groups or released protons. Molecular weight distribution is examined by size-exclusion chromatography or SDS-PAGE. These tests describe average peptide size rather than exact peptide sequences, and results depend on standards and calibration.
Advanced peptide profiling uses liquid chromatography coupled with mass spectrometry to identify fragments and assess batch consistency. Amino acid analysis after acid hydrolysis quantifies the building blocks and can reveal deviations from expected composition. Residual enzyme activity may be monitored in products where active enzymes are undesirable. Allergen tests often use immunoassays for beta-lactoglobulin, but hydrolysis can reduce or alter epitope recognition, so negative results do not prove absence of allergenic potential. Physical tests include particle size, bulk density, and reconstitution behavior.
Regulatory and labeling frameworks vary by country. In the United States, whey protein hydrolysate may be regulated as a food ingredient or a dietary supplement ingredient depending on intended use. In the European Union, it falls under general food law, with additional rules for infant formula and foods for special medical purposes. A claim of hypoallergenicity is not established by hydrolysis alone and generally requires clinical evidence. Open questions remain about how degree of hydrolysis relates to bitterness, nitrogen absorption, and residual allergenicity across different products and processing methods.
Whey protein hydrolysate is derived from whey, the liquid byproduct of cheese-making or casein coagulation. It consists of peptides and free amino acids produced when peptide bonds are cleaved by enzymes or acid. Hydrolysis lowers the average molecular weight and can change solubility, viscosity, and bitterness. The degree of hydrolysis indicates the proportion of peptide bonds broken and distinguishes partial from extensive hydrolysates. Commercial ingredients vary widely in peptide size, mineral content, and lactose level.
Production usually starts with whey protein concentrate or isolate. The material is dissolved, pasteurized, and adjusted to conditions that favor a chosen protease, such as trypsin, pepsin, or papain. Enzyme choice, pH, temperature, and reaction time determine peptide length, terminal residues, and functional behavior. After hydrolysis, the enzyme is inactivated by heat or pH change, and the liquid is clarified, filtered, concentrated, and dried. Membrane filtration can further fractionate peptides and remove some minerals or lactose. The final powder is typically spray-dried.
| Property | Value | Notes |
|---|---|---|
| Protein determination | Kjeldahl nitrogen × 6.38 | Dumas combustion also used |
| Degree of hydrolysis | TNBS, OPA, or pH-stat | Results method-dependent |
| Molecular weight distribution | SEC-HPLC or SDS-PAGE | Reports ranges, not sequences |
| Residual lactose | Enzymatic or HPLC | Relevant for low-lactose products |
| Microbiological limit | Total plate count < 10^4 CFU/g | Typical internal specification, varies |
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Whey protein hydrolysate is a dairy ingredient produced when whey proteins are treated with proteolytic enzymes or, less commonly, acid or heat under controlled conditions. The treatment cleaves peptide bonds and yields shorter peptide chains than those found in intact whey protein. The starting material is usually sweet whey or acid whey from cheese manufacture, concentrated by membrane filtration before hydrolysis. The resulting ingredient retains many amino acids from the original protein but differs in molecular size, solubility, and taste profile.
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Storage stability depends on moisture, temperature, and exposure to oxygen. Dry hydrolysate powders are hygroscopic and can clump or cake when humidity is high. Moisture also promotes Maillard reactions between peptides and residual lactose, leading to browning and flavor changes. Cool, dry, sealed storage slows these reactions, while prolonged warmth can increase off-flavors and reduce solubility. Stability studies often track color, moisture, free amino groups, and microbial load over time to estimate shelf life.
Quality control includes verifying identity, protein content, degree of hydrolysis, and absence of contaminants. Because hydrolysates are often used in foods and supplements, regulations may treat them as food ingredients rather than drugs. Allergen labeling rules can vary, and highly hydrolyzed products are sometimes considered less allergenic, but this depends on peptide size and clinical testing. Sourcing documents should link each lot to raw whey, enzymes, and processing conditions. Independent verification is useful because analytical results can shift with method and laboratory.
Laboratories characterize whey protein hydrolysate using several complementary methods. Nitrogen determination estimates total protein, while size-exclusion chromatography and mass spectrometry reveal peptide size distributions. Degree of hydrolysis can be calculated from free amino groups, pH change, or osmolarity, but each approach has assumptions. Moisture, ash, and mineral content are also measured because they affect shelf life and reconstitution. No single test fully describes a hydrolysate, so specifications usually combine several results.
== E == Electrodialysis Electrolysis Electron microscopy Electron paramagnetic resonance (EPR) also called Electron spin resonance (ESR) Electrophoresis Energy Dispersive Spectroscopy (EDS/EDX) Electron diffraction (ED)
=== Pancreas === The human fetal pancreas begins to develop by the fourth week of gestation. Five weeks later, the pancreatic alpha and beta cells have begun to emerge. Reaching eight to ten weeks into development, the pancreas starts producing insulin, glucagon, somatostatin, and pancreatic polypeptide. During the early stages of fetal development, the number of pancreatic alpha cells outnumbers the number of pancreatic beta cells. The alpha cells reach their peak in the middle stage of gestation. From the middle stage until term, the beta cells continue to increase in number until they reach an approximate 1:1 ratio with the alpha cells. The insulin concentration within the fetal pancreas is 3.6 pmol/g at seven to ten weeks, which rises to 30 pmol/g at 16–25 weeks of gestation. Near term, the insulin concentration increases to 93 pmol/g. The endocrine cells have dispersed throughout the body within 10 weeks. At 31 weeks of development, the islets of Langerhans have differentiated. While the fetal pancreas has functional beta cells by 14 to 24 weeks of gestation, the amount of insulin that is released into the bloodstream is relatively low. In a study of pregnant women carrying fetuses in the mid-gestation and near term stages of development, the fetuses did not have an increase in plasma insulin levels in response to injections of high levels of glucose. In contrast to insulin, the fetal plasma glucagon levels are relatively high and continue to increase during development.
=== Radiological scope === Contrast agents with therapeutic properties have been under development for several years. One example is the design of contrast agents capable of releasing a chemotherapeutic agent locally at the target site, triggered by a stimulus provided by the operator. This localized approach aims to increase treatment efficacy and minimize side effects. For instance, ultrasound-based contrast media, such as microbubbles, can accumulate in hypervascularized tissues and release the active ingredient in response to ultrasound waves, thus targeting a specific area chosen by the sonographer. Another approach involves linking monoclonal antibodies (capable of targeting different molecular targets) to nanoparticles. This strategy enhances the drug's affinity and specificity towards the target and enables visualization of the treatment area, such as using superparamagnetic iron oxide particles detectable by magnetic resonance imaging. Additionally, these particles can be designed to release chemotherapy agents specifically at the site of binding, producing a local synergistic effect with antibody action. Integrating these methods with medical-nuclear techniques, which offer greater imaging sensitivity, may aid in target identification and treatment monitoring.
Sources: en.wikipedia.org
The DSM-5 characterizes diagnosis under several categories—mild, moderate, severe, and extreme—each determined by the number of binges the patient exhibits per week. Mild: 1–3 episodes per week, Moderate: 4–7 episodes per week, Severe: 8–13 episodes per week, Extreme: 14 or more episodes per week Further, the remission states are classified under the following. Partial Remission: Following a previous diagnosis, the average frequency of binge eating episodes decreases to less than one episode per week for a sustained period. Full Remission: Following a previous diagnosis, none of the criteria have been met for a sustained period.
== Comparison of somatostatin receptor agonists and antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had a higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time, and unbound more slowly than the Lu-DOTA-TATE agonist.
Korolev's design bureau produced two prospectuses for circumlunar spaceflight (March 1962 and May 1963), the main spacecraft for which were early versions of his Soyuz design. At the same time, another bureau, OKB-52, headed by Vladimir Chelomey, was developing the LK-1 lunar flyby spacecraft, which would be launched by Chelomey's Proton UR-500 rocket. The Soviet government rejected Korolev's proposals, opting to support Chelomey's project, who gained favor with Khrushchev by employing his son. Officially, the Soviet lunar program was established on August 3, 1964, with the adoption of Soviet Communist Party Central Committee Command 655-268 (On Work on the Exploration of the Moon and Mastery of Space). The circumlunar flights were planned to occur in 1967, and the landings to start in 1968, intending to land a person on the Moon before the Apollo flights. Both of the bureaus submitted their projects for a crewed lunar landing. Korolev's lunar landing program was designated N1/L3, for its N1 super rocket and a more advanced Soyuz 7K-L3 spacecraft, also known as the lunar orbital module ("Lunniy Orbitalny Korabl", LOK), with a crew of two. A separate lunar lander ("Lunniy Korabl", LK), would carry a single cosmonaut to the lunar surface. The N1/L3 launch vehicle had three stages to Earth orbit, a fourth stage for Earth departure, and a fifth stage for lunar landing assist. The combined space vehicle was roughly the same height and takeoff mass as the three-stage US Apollo-Saturn V and exceeded its takeoff thrust by 28% (45,400 kN vs. 33,000 kN.
joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through fifth metatarsophalangeal joint and wrist as small joints, and shoulders, elbows, hip joints, knees, and ankles as large joints: Involvement of 1 large joint gives 0 points Involvement of 2–10 large joints gives 1 point Involvement of 1–3 small joints (with or without involvement of large joints) gives 2 points Involvement of 4–10 small joints (with or without involvement of large joints) gives 3 points Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points serological parameters – including the rheumatoid factor as well as ACPA – "ACPA" stands for "anti-citrullinated protein antibody": Negative RF and negative ACPA gives 0 points Low-positive RF or low-positive ACPA gives 2 points High-positive RF or high-positive ACPA gives 3 points acute phase reactants: 1 point for elevated erythrocyte sedimentation rate, ESR, or elevated CRP value (c-reactive protein) duration of arthritis: 1 point for symptoms lasting six weeks or longer The new criteria incorporate the growing understanding of and the advances in diagnosing and treating RA. In the "new" criteria, serology and autoimmune diagnostics carry major weight, as ACPA detection is appropriate to diagnose the disease in an early state, before joints destructions occur. Destruction of the joints seen in radiological images was a significant point in the ACR criteria from 1987.
Sources: en.wikipedia.org
Allyl alcohol (IUPAC name: prop-2-en-1-ol) is an organic compound with the structural formula CH2=CHCH2OH. Like many alcohols, it is a water-soluble, colourless liquid. It is more toxic than typical small alcohols. Allyl alcohol is used as a precursor to many specialized compounds such as flame-resistant materials, drying oils, and plasticizers. Allyl alcohol is the smallest representative of the allylic alcohols.
== Ecology == As most endoliths are autotrophs, they can generate organic compounds essential for their survival on their own from inorganic matter. Some endoliths have specialized in feeding on their autotroph relatives. The micro-biotope where these different endolithic species live together has been called a subsurface lithoautotrophic microbial ecosystem (SLiME), or endolithic systems within the subterranean lithic biome. Endolithic systems are still at an early stage of exploration. In some cases its biota can support simple invertebrates, most organisms are unicellular. Near-surface layers of rock may contain blue-green algae but most energy comes from chemical synthesis of minerals. The limited supply of energy limits the rates of growth and reproduction. In deeper rock layers microbes are exposed to high pressures and temperatures.
=== Myopathies with central nuclei === Myopathies with central nuclei, such as myotubular myopathy, involves an error in the gene involved in vesicle movement throughout the cell. This creates problems in vesicles reaching the plasma membrane with the cellular components necessary to fuse myoblast, a major step in the formation of the skeletal muscle. This creates structural problems throughout the skeletal muscle and in the Z line of the sarcomere, creating the weakness in the muscle.
Sources: en.wikipedia.org
It is often estimated by TNBS, OPA, or pH-stat methods that quantify free amino groups or released protons. Values depend on assay conditions, protein standard, and calculation method. No single universal protocol exists for all products.
It shows the relative amounts of peptides in different size ranges, commonly by size-exclusion chromatography or SDS-PAGE. A lower average weight indicates more extensive hydrolysis. It does not identify specific peptide sequences or biological effects.
No. Immunoassays can measure residual protein or specific whey proteins, but hypoallergenicity requires clinical evaluation. Hydrolysis may reduce IgE-binding, yet some peptides can remain reactive. Label claims are regulated separately from analytical results.
Whey protein hydrolysate is whey protein that has been treated with enzymes or acid to break peptide bonds into smaller peptides. It is not a different protein source; it is a modified form of whey protein. Commercial products range from partially to extensively hydrolyzed.